Actin alpha 2, smooth muscle (ACTA2)

Actin alpha 2, smooth muscle (ACTA2), encodes alpha-smooth muscle actin, a crucial contractile cytoskeletal protein predominantly found in vascular and visceral smooth muscle cells. It is essential for smooth muscle contraction, enabling blood vessel tone, organ motility, and wound healing by forming the sarcomeric backbone of the contractile apparatus. ACTA2 is also widely used as a biomarker for myofibroblast formation in fibrosis and tumor stroma due to its inducible expression outside the vascular system. Mutations in ACTA2 are a leading cause of genetic vascular disorders, including familial thoracic aortic aneurysm and dissection, coronary artery disease, ischemic stroke, Moyamoya disease, and other syndromes with impaired smooth muscle function. Overexpression of ACTA2 is observed in several aggressive cancers and is associated with poor prognosis due to enhanced cellular migration and metastatic potential. There are currently no specific clinically approved drugs directly targeting ACTA2, but its role in smooth muscle biology, fibrosis, and cancer makes it an emerging research and potential therapeutic target.

Other names

Actin, aortic smooth muscleActin, alpha 2, smooth muscle, aortaAlpha-smooth muscle actinAlpha-actin-2SMAACTSAACTVSGIG46SMDYSCell growth-inhibiting gene 46 proteinAlpha-cardiac actinASMASMactin

Targeting ACTA2 can modulate smooth muscle contraction and cell motility by affecting actin polymerization and cytoskeleton dynamics. In cancer, ACTA2 silencing reduces cell migration and invasion. TGF-β pathway inhibitors indirectly influence ACTA2 expression and fibrotic response.